
NICE plans to use broader range of data in guidance
pharmafile | February 5, 2020 | News story | Research and Development | NHS, NHS NICE, NICE
The British National Institute for Care Excellence has said it plans to use a broader range of data and analytics in its guidance. This will include real-world evidence and electronic health records.
NICE approved the plan in principle last month. Health Secretary Matt Hancock said that the agency has a duty to ensure their “rules, processes and ways or working” are up to date.
NICE received 130 comments on its process from clinicians, industry and patient groups. It pledged to make sure it rules and processes are up to date to handle new types of medicines.
This new process will involve making the range of data include patient records, real world evidence from health and social care practice outside of trials, such as registries and clinical audits. This should result in improved guidance and allow existing recommendations to be updated more quickly, said the agency.
NICE intends to provide additional details on its plans in a public board meeting next month.
The plans are intended primarily for the development of guidance aimed at health and social care systems. However there is some overlap with its health technology evaluation methods, which are used to review new therapies for use on the NHS.
Conor Kavanagh
Related Content

A community-first future: which pathways will get us there?
In the final Gateway to Local Adoption article of 2025, Visions4Health caught up with Julian …

The Pharma Files: with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust
Pharmafile chats with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust, about …

Is this an Oppenheimer moment for the life sciences industry?
By Sabina Syed, Managing Director at Visions4Health In the history of science, few initiatives demonstrate …






